Showing results (71-80 of 178) with videos related to

Sort By:
Pageof 18
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|November 5, 2014
Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor controlAnouchka Modesto, Anne Laprie, Laure Vieillevigne, et al.
Melanoma Research|September 1, 2017
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combinationAmélie Aboudaram, Anouchka Modesto, Léonor Chaltiel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 28, 2015
Guideline sheets on the side effects of anticancer drugs are useful for general practitionersMarie-Eve Rouge-Bugat, Donia Lassoued, Joy Bacrie, et al.
BMC Cancer|May 2, 2023
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol studyGwenaelle Gravis, Patricia Marino, Daniel Olive, et al.
Bulletin Du Cancer|May 20, 2020
[COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie]Pascale Grosclaude, David Azria, Rosine Guimbaud, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 17, 2019
Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process?Anouchka Modesto, Thibaut Galissier, Amélie Lusque, et al.
Current Clinical Pharmacology|November 16, 2011
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancerPeggy Gandia, Cecile Arellano, Quentin Chalret du Rieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyHenri Roché, Louise Yelle, Francesco Cognetti, et al.
Investigational New Drugs|February 12, 2009
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxicsNicolas Penel, Jean-Pierre Delord, Marie-Edith Bonneterre, et al.
Investigational New Drugs|November 4, 2024
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trialMathilde Morisseau, Carlos Gomez-Roca, Marie Viala, et al.
Pageof 18